Publications by authors named "Parth Vashi"

Claim this Profile
P
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
Rong Chen, Dmitry Gultyaev, Johanna Lister, Rong Han, Nan Hu, Parth Vashi

BMC Med Res Methodol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
Parth Vashi, Katharine Batt, Robert Klamroth, Maria Elisa Mancuso, Renata Majewska

J Blood Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII).
Jane R Wells, Adam Gater, Chris Marshall, Theo Tritton, Parth Vashi

Patient· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A.
Katharine Batt, Wei Gao, Rajeev Ayyagari, Céline Deschaseaux, Parth B Vashi

J Blood Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis